CJC-1295 and Hormonal Contraceptives: Interaction Risk, Mechanism, and Clinical Guidance
HealthRX.com
No established interaction between CJC-1295 and birth control
Key numbers
- 49 daysLongest duration of a human CJC-1295 study, all in healthy volunteersSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- 5.8 to 8.1 daysEstimated half-life of CJC-1295 DAC after one injection in humansSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- 14 to 34%Share of women on norgestimate and ethinyl estradiol with unscheduled bleeding per cycle in year oneSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
At a glance
- Interaction status / Not established; CJC-1295 is not FDA-approved [1]
- Human data / Three published studies, all of the DAC form, all in healthy volunteers [1]
- Label concern / CYP3A4 inducers can lower COC levels; CJC-1295 is not named [3]
- Lab finding / GH increased CYP3A4 expression in cultured human hepatocytes [4]
- Contraceptive hormone data / Not among the reported outcomes of the CJC-1295 studies [2][8]
- Dose adjustment / No CJC-1295-specific adjustment has been established [1][2]
Does CJC-1295 interact with hormonal birth control?
No published human study of CJC-1295 has tested it with a combined pill, patch, ring, or progestin-only pill. FDA identified only three published human studies, all of the DAC form in healthy volunteers [1]. The longest ran up to 49 days, and their outcomes were growth hormone, IGF-I and CJC-1295 levels or GH pulsatility, not contraceptive hormones [2][8]. CJC-1295 is not an FDA-approved drug; FDA found no approved product containing any form of it in the countries it searched [1].
The relevant labels cover Sprintec (norgestimate and ethinyl estradiol), Twirla (levonorgestrel and ethinyl estradiol patch), NuvaRing (etonogestrel and ethinyl estradiol ring), and Slynd (drospirenone) [3][5][6][7]. The Sprintec label states that no drug-drug interaction studies were conducted with Sprintec [3].
Why might a GH-raising peptide be suspected?
CJC-1295 acts on the pituitary to raise growth hormone and, through GH, IGF-I [2][8]. After one injection of CJC-1295 DAC, mean GH rose 2- to 10-fold for 6 days or more and IGF-I rose 1.5- to 3-fold for 9 to 11 days; the estimated half-life was 5.8 to 8.1 days [2]. A second study found trough GH rose about 7.5-fold, mean GH rose 46%, and IGF-I rose 45% [8].
In cultured human hepatocytes, GH treatment substantially increased CYP3A4 gene expression [4]. Ethinyl estradiol is metabolized partly by CYP3A4, with 2-hydroxylation described as the major oxidative pathway [9]. These are separate laboratory and label findings. No source shows that CJC-1295 changes contraceptive hormone levels in people.
What do the contraceptive labels say?
The Sprintec label says CYP3A4 inducers may decrease plasma concentrations of combined oral contraceptives and potentially reduce effectiveness or increase breakthrough bleeding. It names phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, topiramate, rifabutin, rufinamide, aprepitant, and St. John's wort [3]. For those inducers, the label says to counsel use of a back-up or alternative method and to continue back-up for 28 days after the inducer is stopped [3]. Twirla and Slynd carry the same CYP3A4 inducer advice [5][7]. CJC-1295 is not among the examples named [3].
Does birth control change CJC-1295?
A 1991 study of postmenopausal women (7 per group) found that oral ethinyl estradiol 20 micrograms daily for 2 months lowered serum IGF-I from 0.70 to 0.47 U/mL, while transdermal estradiol raised IGF-I from 0.86 to 1.10 U/mL [10]. That study did not use CJC-1295 and did not enroll contraceptive users, so it does not show how a combined pill would change the IGF-I response to CJC-1295.
What is the practical answer?
No CJC-1295-specific dose adjustment has been established, because the available human studies did not test the combination or measure contraceptive hormone levels [1][2]. CJC-1295 has no FDA-approved dose [1]. The interaction is unproven and unmeasured, not shown to be absent.
Questions worth asking
Frequently asked questions
Does CJC-1295 make birth control less effective?
Is CJC-1295 a CYP3A4 inducer?
Should I use backup birth control with CJC-1295?
Does birth control affect CJC-1295?
What if I get breakthrough bleeding?
Are all hormonal contraceptives the same here?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
Can you take peptides and birth control together?
Not established. No published human study has tested CJC-1295 with a combined pill, patch, ring, or progestin-only pill. Its three human studies were in healthy volunteers and did not measure contraceptive hormone levels, so the interaction is unproven and unmeasured, not shown to be absent.
What supplements should you not take with birth control pills?
St. John's wort is the supplement the labels name. It is listed among CYP3A4 inducers that may decrease plasma concentrations of combined oral contraceptives and potentially reduce effectiveness or increase breakthrough bleeding. The labels say to counsel a back-up or alternative method when such an inducer is used, and to continue back-up for 28 days after it is stopped.
References
Show all 10 referencesHide references
- U.S. Food and Drug Administration.
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.
- U.S. National Library of Medicine, DailyMed. Sprintec norgestimate and ethinyl estradiol tablets (Teva) prescribing information. Sprintec norgestimate and ethinyl estradiol tablets (Teva) label
- Liddle C, Goodwin BJ, George J, Tapner M, Farrell GC. Separate and interactive regulation of cytochrome P450 3A4 by triiodothyronine, dexamethasone, and growth hormone in cultured hepatocytes. J Clin Endocrinol Metab. 1998;83(7):2411-6.
- U.S. National Library of Medicine, DailyMed. Twirla levonorgestrel and ethinyl estradiol transdermal system (Agile) (levonorgestrel/ethinyl estradiol) prescribing information. Twirla levonorgestrel and ethinyl estradiol transdermal system (Agile) (levonorgestrel/ethinyl estradiol) label
- U.S. National Library of Medicine, DailyMed. NuvaRing etonogestrel and ethinyl estradiol vaginal ring (Advanz) prescribing information. NuvaRing etonogestrel and ethinyl estradiol vaginal ring (Advanz) label
- U.S. National Library of Medicine, DailyMed. Slynd drospirenone tablets (Exeltis) prescribing information. Slynd drospirenone tablets (Exeltis) label
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-7.
- Zhang H, Cui D, Wang B, Han YH, Balimane P, Yang Z, et al. Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug. Clin Pharmacokinet. 2007;46(2):133-57.
- Weissberger AJ, Ho KK, Lazarus L. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. J Clin Endocrinol Metab. 1991;72(2):374-81.